Optimal Heart Failure Medical Therapy and Mortality in Survivors of Cardiogenic Shock: Insights From the FRENSHOCK Registry.
Kensuke MatsushitaClément DelmasBenjamin MarchandotFrancois RoubilleNicolas LamblinGuillaume LeurentBruno LevyMeyer ElbazSebastien ChampionPascal LimFrancis SchneiderHadi KhachabAdrien CarmonaAntonin TrimailleBourenne JeremyMarie-France SerondeGuillaume SchurtzBrahim HarbaouiGerald VanzettoCaroline BiendelVincent LabbeNicolas CombaretJacques MansouratiEmmanuelle FilippiJulien MaizelHamid MerdjiBenoit LattucaEdouard GerbaudEric BonnefoyEtienne PuymiratLaurent BonelloOlivier MorelPublished in: Journal of the American Heart Association (2024)
In survivors of CS, the one-year mortality rate was significantly lower in those with triple GDMT. Therefore, this study suggests that intensive HF therapy should be considered in patients following CS.
Keyphrases
- heart failure
- end stage renal disease
- cardiovascular events
- young adults
- newly diagnosed
- ejection fraction
- healthcare
- risk factors
- prognostic factors
- peritoneal dialysis
- left ventricular
- acute heart failure
- coronary artery disease
- stem cells
- atrial fibrillation
- mesenchymal stem cells
- cardiovascular disease
- patient reported outcomes
- bone marrow
- cell therapy
- patient reported